Akdeniz University School of Medicine, Department of Anesthesiology and Intensive Care, Turkey
Antalya, Turkey (Türkiye)
NCT Number: NCT06490640
Spontaneous subarachnoid haemorrhage (SAH) is a serious cerebrovascular disease with high morbidity and mortality.Determining the factors associated with mortality in the ICU follow-up and treatment of patients with spontaneous SAH is very important for clarifying these uncertainties and improving ICU outcomes.In the literature, there are very few studies analysing ICU mortality and mortality-related factors in this patient group.The aim of this study was to determine the demographic/clinical characteristics and factors affecting the mortality of spontaneous SAH patients admitted in the ICU.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Antalya, Turkey (Türkiye)
Patients aged 18 years and older who were diagnosis of spontaneous SAH and admitted the ICU were included in the study. The diagnosis of spontaneous SAH was based on the brain computed tomography (CT) or lumbar puncture. Patients with a final outcome (survival or mortality) in our centre were included in the analysis were included. Only patients admitted to the ICU for the first time were included. Patients with traumatic SAH, history of significant head trauma in the previous two weeks (any abnormality on brain CT requiring hospitalisation for more than 24 hours), pregnancy and length of ICU stay ≤24 hours were excluded.The clinical and radiological severity of the patients at ICU admission was according to Acute Physiological and Chronic Health Evaluation-II score (APACHE II), Glasgow Coma Scale (GCS), Modified Fisher Scale, World Federation of Neurological Societies (WFNS) and Hunt and Hess (H&H) grading systems.Demographic and clinical data derived and analyzed included age, sex, smoking history, comorbidities. Presenting signs and symptoms, diagnoses responsible for spontaneous SAH (aneurysm, arterial malformation, etc.), site of aneurysm, risk factors, location of the aneurysm, risk factors, blood pressure during ICU admission, and scores from grading systems indicating clinical and radiological severity of the disease were recorded. Procedures for spontaneous SAH, complications during ICU follow-up (vasospasm, meningitis, electrolyte disturbances, rebleeding, DCI, VIP, sepsis/septic shock) and treatments, duration of ICU stay and mechanical ventilation, ICU outcome (survival or mortality), causes of mortality and brain death status were recorded. According to the outcome of the ICU process, the patients were divided into two groups as survival and mortality.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
consists of surviving patients
consists of deceased patients
Time frame: 01 January 2019-31 December 2023
determine mortality and its causes in patients with spontaneous subarachnoid haemorrhage
Time frame: 01 January 2019-31 December 2023
evaluate the clinical characteristics and factors affecting mortality in subarachnoid haemorrhage
Melike Cengiz
Other
Factors Influencing the Mortality of Patients With Subarachnoid Haemorrhage in the Intensive Care Unit
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07315048
Brain Diseases, Cardiovascular Diseases
Chengdu, Sichuan, China
View Trial DetailsNCT04377347
Brain Diseases, Cardiovascular Diseases
Copenhagen, Denmark
View Trial DetailsNCT03786068
Brain Diseases, Cardiovascular Diseases
Copenhagen, Denmark
View Trial DetailsNCT01801306
Brain Diseases, Cardiovascular Diseases
Heidelberg, Germany
View Trial Details